Monday, October 24, 2005
| 7:30 - 8:00 am | Registration |
| Session I: Opening Remarks and Welcome |
| 8:00 - 8:15 am | Welcoming Remarks | Peter Greenwald, Director
Division of Cancer Prevention
National Cancer Institute
Sudhir Srivastava, Chief
Cancer Biomarkers Research Group
John Milner, Chief
Nutritional Sciences Research Group |
| 8:15 - 8:20 am | Setting the Stage | Padma Maruvada and Young Kim
Division of Cancer Prevention
National Cancer Institute |
Session II: Overview of Metabolomics
Objective: This session will compare and contrast the evolution of metabolomics, including its definitions, from its predecessors or counterparts and discuss convergences and divergences |
| 8:20 - 8:50 am | What Is Metabonomics? | Julian Griffin |
Session II: Methodological and Technological Issues and Concerns (Moderator: Sharon Ross)
Objective: This session will describe prevailing technologies, including those with dual purposes, reagents, and
instrumentations, required infrastructures, etc |
| 8:50 - 9:20 am | State-of-the Art Technologies on Metabolomics | Stephen Brown |
| 9:20 - 9:30 am | Discussion |
| 9:30 am - 10:00 am | Pathway Discovery Through the Association of Metabolomics and Mass Isotopomer Analysis | Henri Brunengraber |
| 10:00 - 10:10 am | Discussion |
| 10:10 - 10:25 am | Morning Break |
| 10:25 - 10:55 am | Evolutionary Optimization
in Metabolomics | Douglas Kell |
| 10:55 - 11:05 am | Discussion |
| 11:05 - 11:35 am | Group Discussion | Douglas Burrin, Moderator |
Session III: Use of Metabolomics for Cancer Research (Moderator: Paul Wagner)
Objective: To identify issues on the application of metabolomics in cancer research |
| 11:35 - 12:05 pm | A Crossroad to Tumor Metabolome:
Tumor M2 Pyruvate Kinase | Sybille Mazurek |
| 12:05 - 12:15 pm | Discussion |
| 12:15 - 1:15 pm | Lunch (on your own) |
| 1:15 - 1:45 pm | Metabolomics by Magnetic Resonance:
From Molecules to Man | John Griffiths |
| 1:45 - 1:55 pm | Discussion |
| 1:55 - 2:25 pm | Metabolomic Profiling of Human
Cancer With Ex Vivo Tissue MR Spectroscopy | Leo Cheng |
| 2:25 - 2:35 pm | Discussion |
| 2:35 - 3:05 pm | Group Discussion | Sudhir Srivastava, Moderator |
| 3:05 - 3:20 pm | Afternoon Break |
Session IV: Impact of Cancer Modifiers on Metabolic Profiling (Moderator: Elizabeth Yetley)
Objective: To discuss metabolomic arrays, spectroscopic profiles, and other metabolites-based phenotyping in relation to
its application for patients, stratification for responders and non-responders to dietary components, drugs, and
toxic agents |
| 3:20 - 3:50 pm | Dynamics of Glucose Metabolism
and Cancer | Paul Lee |
| 3:50 - 4:00 pm | Discussion |
| 4:00 - 4:30 pm | Lipidomic Profiling Eicosanoid
Changes in Carcinogenesis | Edward Dennis |
| 4:30 - 4:40 pm | Discussion |
| 4:40 - 5:10 pm | Metabolic Profiling in Drug
Discovery and Development | Christopher Newgard |
| 5:10 - 5:20 pm | Discussion |
| 5:20 - 5:50 pm | Group Discussion | John Milner, Moderator |
| 5:50 pm | Adjourn |
Tuesday, October 25, 2005Session V: Models for Studying Metabolomic Approaches (Moderator: David Goldstein)
Objective: To identify challenges in application of metabolomics in cancer research |
| 8:30 - 9:00 am | Analysis of Metabolic Phenotype Risto Kauppinen Changes in Response to Therapy in Cancer Animal Models |
| 9:00 - 9:10 am | Discussion |
| 9:10 - 9:40 am | Other Models To Understand
the Cancer Cell Metabolic Flux | Zoltan Oltvai |
| 9:40 - 9:50 am | Discussion |
| 9:50 - 10:20 am | Metabolomics in the Study
of CNS Disorders | Rima Kaddurah-Daouk |
| 10:20 - 10:30 am | Discussion |
| 10:30 - 11:00 am | Group Discussion | Bruce Kristal, Moderator |
Session VI: Integration of Metabolomics Into Systems Biology (Moderator: Lee Moore)
Objective: To discuss a systems biology approach to mapping small molecules in metabolic pathways and biochemical
networks in relation to phenotypic changes |
| 11:00 - 11:30 am | Integration of all "Omics" | Pedro Mendes |
| 11:30 - 11:40 am | Discussion |
| 11:40 - 12:10 pm | Systems Approach to Cancer | Michael Liebman |
| 12:10 - 12:20 pm | Discussion |
| 12:20 - 12:50 pm | Group Discussion | Jennifer Couch, Moderator |
| 12:50 - 1:50 pm | Lunch (on your own) |
| Session VII: Breakouts |
| 1:50 - 3:10 pm | Breakouts I, II, and III |
Breakout I: Chair: Lance Liotta
Metabolomics vs Other Omics Co-Chair: Samir Hanash
- What information can metabolomics provide that genomics and/or proteomics may not be able to address?
- Can metabolic profiling identify individuals who will and who will not get the benefit from treatments
with either drugs or dietary components?
- Can a metabolomics approach serve as a functional annotation that links to the systems biology?
Breakout II: Chair: Bruce Kristal
Application of Metabolomics
in Understanding Tumor Cell Behavior
Co-Chair: Gil Omenn
- What are the key metabolites relevant to tumor cell behavior that should be measured quantitatively in
cancer research?
- Which fluids, cells and/or tissues should be sampled for the examination?
- Can metabolomic approaches be used to discover and further develop metabolic biomarkers that are
distinct in tumor cell environment or in pre-cancerous tissues?
Breakout III: Chair: Henri Brunengraber
Evaluation of Technologies Co-Chair: Alan Kleinfeld
- What are the strengths and weaknesses of the most commonly used metabolomics technologies?
- Which bioinformatics tools can be used for the metabolomics data analysis?
- How can imaging be used to detect metabolites in cells or organs?
|
| Session VIII: Reports on Breakouts |
| 3:10 - 3:20 pm | Breakout I | Lance Liotta |
| 3:20 - 3:30 pm | Breakout II | Bruce Kristal |
| 3:30 - 3:40 pm | Breakout III | Henri Brunengraber |
| 3:40 - 3:50 pm | Future Directions | Young Kim and Padma Maruvada |
| 3:50 pm | Adjourn |
